ZA991951B - Compound and its use. - Google Patents

Compound and its use.

Info

Publication number
ZA991951B
ZA991951B ZA9901951A ZA991951A ZA991951B ZA 991951 B ZA991951 B ZA 991951B ZA 9901951 A ZA9901951 A ZA 9901951A ZA 991951 A ZA991951 A ZA 991951A ZA 991951 B ZA991951 B ZA 991951B
Authority
ZA
South Africa
Prior art keywords
compound
Prior art date
Application number
ZA9901951A
Other languages
English (en)
Inventor
Lorraine Mary Edmeades
Derek Anthony Hill
Terence William Packham
Nigel Arthur Griffith-Skinner
Graham Thronton Hill
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA991951(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA991951B publication Critical patent/ZA991951B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9901951A 1998-06-10 1999-03-10 Compound and its use. ZA991951B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
ZA991951B true ZA991951B (en) 1999-08-16

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901951A ZA991951B (en) 1998-06-10 1999-03-10 Compound and its use.

Country Status (31)

Country Link
US (1) US6333198B1 (ru)
EP (2) EP0963980B1 (ru)
JP (1) JP2989189B1 (ru)
KR (1) KR100322354B1 (ru)
CN (2) CN1238454A (ru)
AP (3) AP9901481A0 (ru)
AR (1) AR014074A1 (ru)
AT (1) ATE218552T1 (ru)
AU (1) AU2031999A (ru)
BR (1) BR9900984A (ru)
CA (1) CA2265194C (ru)
DE (1) DE69901656T2 (ru)
DK (1) DK0963980T3 (ru)
EA (1) EA000666B1 (ru)
ES (1) ES2178342T3 (ru)
GB (1) GB9812413D0 (ru)
HR (1) HRP990074A2 (ru)
HU (1) HUP9900592A3 (ru)
ID (1) ID22957A (ru)
MA (1) MA24777A1 (ru)
NO (2) NO991151L (ru)
NZ (1) NZ334590A (ru)
PE (1) PE20000332A1 (ru)
PL (1) PL331870A1 (ru)
PT (1) PT963980E (ru)
SG (1) SG85628A1 (ru)
SI (1) SI0963980T1 (ru)
TR (1) TR199900520A3 (ru)
UY (1) UY25946A1 (ru)
YU (1) YU12399A (ru)
ZA (1) ZA991951B (ru)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AP2003002820A0 (en) 2000-12-29 2003-06-30 Pfizer Ltd "Process for making amlodipine maleate"
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
WO2002053540A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Aspartate derivative of amlodipine as calcium channel antagonist
CA2433284A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
EP1309554A1 (en) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Amide derivative of amlodipine
CA2433190C (en) 2000-12-29 2005-11-15 Pfizer Limited Amlodipine hemimaleate
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
IL164155A0 (en) * 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
JP4733047B2 (ja) 2003-12-02 2011-07-27 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの特性評価のためのリファレンス・スタンダード
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
JP2007518826A (ja) * 2004-01-30 2007-07-12 テバ ファーマシューティカル インダストリーズ リミティド モンテルカスト遊離酸多形体
MD2823G2 (ru) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Способ количественного определения склареола в экстрактах, полученных из шалфея мускатного
WO2005105751A1 (en) * 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
TW200613294A (en) * 2004-04-26 2006-05-01 Teva Gyogyszergyar Reszvenytarsasag Process for preparation of mycophenolic acid and ester derivatives thereof
US7358247B2 (en) * 2004-04-27 2008-04-15 TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság Mycophenolate mofetil impurity
CA2561387A1 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. An isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
EP1673351A1 (en) * 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
JP2008506784A (ja) * 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 結晶形ミコフェノール酸・ナトリウム
CN1976894A (zh) * 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
CA2578750A1 (en) * 2004-09-04 2006-03-16 Teva Pharmaceutical Industries, Ltd. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
JP2007512357A (ja) * 2004-09-28 2007-05-17 テバ ファーマシューティカル インダストリーズ リミティド 不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20060173215A1 (en) * 2005-01-11 2006-08-03 Valeriano Merli Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
CA2680693A1 (en) * 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
JP2008530028A (ja) * 2005-02-24 2008-08-07 テバ ファーマシューティカル インダストリーズ リミティド リネゾリッド中間体の調製方法
MX2007011254A (es) * 2005-03-14 2007-10-18 Teva Pharma Proceso para la preparacion de (s)-(+)-n,n-dimetil-3-(1- naftaleniloxi)-3-(2-tienil)propanamina opticamente activa.
JP2008501721A (ja) * 2005-04-05 2008-01-24 テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節
CA2603129A1 (en) * 2005-04-06 2006-10-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
US7687622B2 (en) * 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
MX2007000524A (es) * 2005-05-10 2007-03-28 Teva Pharma Metodo para la preparacion de pregabalina y sales de ella.
EP1879852A1 (en) * 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Pregabalin free of lactam and a process for preparation thereof
US20070043241A1 (en) * 2005-05-10 2007-02-22 Lilach Hedvati Optical resolution of 3-carbamoylmethyl-5-methylhexanoic acid
CA2604600A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of isobutylglutaric acid and a process for preparation thereof
JP2008507565A (ja) 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド シナカルセトの精製
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof
WO2007002722A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. Synthesis of anastrozole and purification of one of its intermediate
KR100899585B1 (ko) * 2005-07-05 2009-05-27 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
US7563923B2 (en) * 2005-09-19 2009-07-21 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
EP1863782A1 (en) 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
CA2625858A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
WO2007126886A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceuticals Usa, Inc. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
WO2007139933A2 (en) * 2006-05-24 2007-12-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
CA2649117A1 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. The use of enzymatic resolution for the preparation of intermediates of pregabalin
US20080015385A1 (en) * 2006-05-31 2008-01-17 Lilach Hedvati Preparation of (S)-pregabalin-nitrile
US20080009050A1 (en) * 2006-06-29 2008-01-10 Zdenek Pokluda Regulation of acid metabolite production
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CA2659290A1 (en) * 2006-08-14 2008-02-21 Jean-Paul Roduit A process for the preparation of lamotrigine
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
US8097754B2 (en) * 2007-03-22 2012-01-17 Teva Pharmaceutical Industries Ltd. Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
EP2024506A1 (en) * 2007-04-11 2009-02-18 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Method for reducing impurity level in mycophenolic acid fermentation
EP2098519A1 (en) * 2007-05-31 2009-09-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20090137842A1 (en) * 2007-10-03 2009-05-28 Vollerner Yuri Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
EP2252574A1 (en) * 2008-03-06 2010-11-24 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
KR20100107500A (ko) * 2008-06-23 2010-10-05 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
KR101409554B1 (ko) * 2010-03-29 2014-06-19 플리바 흐르바츠카 디.오.오. Ｏ-데스메틸벤라팍신 푸마레이트의 결정형
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059987B1 (en) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((n-guanidino)-imino) toluenes
EP0021120B1 (en) 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
PT800520E (pt) * 1994-12-30 2002-11-29 Wellcome Found Processo para a preparacao de lamotrigina
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
NO20032753L (no) 1999-12-13
NO991151D0 (no) 1999-03-10
DK0963980T3 (da) 2002-09-16
UY25946A1 (es) 2000-12-29
TR199900520A2 (en) 2000-01-21
AP9901481A0 (en) 1999-03-31
KR20000005611A (ko) 2000-01-25
KR100322354B1 (ko) 2002-02-07
PT963980E (pt) 2002-10-31
HRP990074A2 (en) 2000-10-31
EP0963980A3 (en) 2000-05-31
CN1238454A (zh) 1999-12-15
SI0963980T1 (en) 2002-12-31
TR199900520A3 (tr) 2000-01-21
NZ334590A (en) 2000-07-28
ES2178342T3 (es) 2002-12-16
CN1306210A (zh) 2001-08-01
PE20000332A1 (es) 2000-04-10
EP1170588A1 (en) 2002-01-09
MA24777A1 (fr) 1999-10-01
YU12399A (sh) 2002-08-12
SG85628A1 (en) 2002-01-15
NO991151L (no) 1999-12-13
BR9900984A (pt) 2000-05-02
HUP9900592A3 (en) 2002-04-29
CA2265194C (en) 2000-10-10
EP0963980A2 (en) 1999-12-15
AP0102286A0 (en) 2000-09-10
AR014074A1 (es) 2001-01-31
GB9812413D0 (en) 1998-08-05
PL331870A1 (en) 1999-12-20
JP2989189B1 (ja) 1999-12-13
HUP9900592A2 (hu) 2000-04-28
EA000666B1 (ru) 2000-02-28
AP2001002286A0 (en) 2001-12-31
EP0963980B1 (en) 2002-06-05
JP2000009714A (ja) 2000-01-14
ATE218552T1 (de) 2002-06-15
AU2031999A (en) 2000-01-06
DE69901656D1 (de) 2002-07-11
DE69901656T2 (de) 2003-01-30
ID22957A (id) 1999-12-23
US6333198B1 (en) 2001-12-25
EA199900159A1 (ru) 1999-12-29
NO20032753D0 (no) 2003-06-17
HU9900592D0 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
ZA991951B (en) Compound and its use.
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
GB9712317D0 (en) Composition, compound and use
GB9818914D0 (en) Use
GB9817235D0 (en) Compound,composition and use
EP1056455A4 (en) EPIMORPHIN COMPOUND AND USE OF THE SAME
GB9817236D0 (en) Compound,composition and use
ZA992443B (en) Hydroxy-methyl-hexanones.
GB9718876D0 (en) Compound,composition and use
EP1058550A4 (en) SUBSTITUTED SEMICARBAZIDES AND THEIR USE
ZA200006206B (en) Benzazole compounds and their use.
GB9903447D0 (en) Compound, composition and use
ZA993123B (en) Trisresorcinyltriazines.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
GB0100361D0 (en) Compound, composition and use
GB9723859D0 (en) Compound,composition and use
GB9814227D0 (en) The worthybag
GB9828004D0 (en) Use
GB9807503D0 (en) Use
GB9801584D0 (en) The maitriser
HK1028588A1 (en) Case.
GB9723853D0 (en) Compound, composition and use
GB9723856D0 (en) Compound,composition and use
GB9723858D0 (en) Compound,composition and use